BIOLINERX Trademark

Trademark Overview

On Tuesday, May 23, 2023, a trademark application was filed for BIOLINERX with the United States Patent and Trademark Office. The USPTO has given the BIOLINERX trademark a serial number of 79377711. The federal status of this trademark filing is IR CANCELLED - REGISTRATION PENDING TRANSFORMATION as of Friday, August 29, 2025. This trademark is owned by BioLineRx Ltd.. The BIOLINERX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical product development services, namely, pharmaceutical product development through the discovery of compounds that helps for the treatment of a variety of diseases and symptoms; pharmaceutical product development services for a wide variety of diseases and symptoms, namely, neuropathic pain, acute kidney injury, inflammatory bowel disease, adult diabetes, weight loss among cancer patients, bacterial infections, rheumatoid arthritis, celiac disease, psoriasis, solid cancerous tumors, myocardial infarction, schizophrenia and prostate cancer; pharmaceutical product development services of new compounds for use in medicines for oncology patients; pharmaceutical research services; research and development services in the field of biotechnology
biolinerx

General Information

Serial Number79377711
Word MarkBIOLINERX
Filing DateTuesday, May 23, 2023
Status403 - IR CANCELLED - REGISTRATION PENDING TRANSFORMATION
Status DateFriday, August 29, 2025
Registration Number7484131
Registration DateTuesday, August 27, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 11, 2024

Trademark Statements

Goods and ServicesPharmaceutical product development services, namely, pharmaceutical product development through the discovery of compounds that helps for the treatment of a variety of diseases and symptoms; pharmaceutical product development services for a wide variety of diseases and symptoms, namely, neuropathic pain, acute kidney injury, inflammatory bowel disease, adult diabetes, weight loss among cancer patients, bacterial infections, rheumatoid arthritis, celiac disease, psoriasis, solid cancerous tumors, myocardial infarction, schizophrenia and prostate cancer; pharmaceutical product development services of new compounds for use in medicines for oncology patients; pharmaceutical research services; research and development services in the field of biotechnology

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status CodeH - NOT AVAILABLE
Class Status DateThursday, August 28, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBioLineRx Ltd.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressIL
Party NameBioLineRx Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressIL
Party NameBioLineRx Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIL

Trademark Events

Event DateEvent Description
Friday, September 1, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 5, 2023APPLICATION FILING RECEIPT MAILED
Thursday, February 15, 2024ASSIGNED TO EXAMINER
Thursday, August 31, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, March 12, 2024REFUSAL PROCESSED BY MPU
Tuesday, May 7, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 20, 2024NON-FINAL ACTION WRITTEN
Wednesday, February 21, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 13, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, April 2, 2024REFUSAL PROCESSED BY IB
Tuesday, May 7, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 7, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 7, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 7, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, May 7, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, May 7, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, May 7, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 7, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 11, 2024PUBLISHED FOR OPPOSITION
Wednesday, May 22, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 11, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, July 25, 2024TEAS REQUEST FOR TRANSFORMATION RECEIVED
Friday, November 29, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 27, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, August 27, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Thursday, September 11, 2025DEATH OF INTERNATIONAL REGISTRATION
Thursday, September 11, 2025NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Saturday, March 8, 2025FINAL DECISION TRANSACTION PROCESSED BY IB
Sunday, January 26, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, January 27, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, February 14, 2025FINAL DISPOSITION NOTICE SENT TO IB
Friday, February 14, 2025FINAL DISPOSITION PROCESSED
Saturday, February 15, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

Related Keywords

biolinerx pharmaceutical development services product diseases symptoms disease variety compounds namely